NCT01319539终止2 期
Pre-surgical Evaluation of MK-2206 in Patients With Operable Invasive Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 12
- 试验地点
- 3
- 主要终点
- Change in pAKT Levels
研究概览
简要总结
This phase II trial is studies how well Akt inhibitor MK2206 works in treating patients with stage I-III breast cancer that can be removed by surgery. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
详细描述
PRIMARY OBJECTIVES:
I. To assess for a decrease in phosphorylated (phospho)-protein kinase B (Akt) (Ser^473) levels in tissue after a pre-surgical trial of weekly MK2206 (Akt inhibitor MK2206) (2 doses) in patients with operable invasive breast cancer.
SECONDARY OBJECTIVES:
I. To evaluate the effects of MK2206 on the immunohistochemical expression of other phosphatidylinositide 3-kinase (PI3K)/AKT pathway biomarkers on pre-and post-MK2206 tumor tissue, such as phospho-S6 kinase.
II. To assess modulation of PI3K/AKT signaling following MK2206 use with reverse-phase protein microarray analysis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically-confirmed operable invasive breast cancer and have undergone core needle biopsy with an anticipated surgical resection for residual disease after enrollment
- •Patients must have clinical stage I-III invasive breast (invasive tumor must be clinically at least >= T1c by radiograph or palpation)
- •Patients must have available tissue from core biopsies for biomarker assessment; it is recommended that at least 4 cores be performed with 12 gauge (or smaller gauge) needles; this includes cores underneath ultrasound-guidance
- •Patients are planning to undergo surgical treatment with either segmental resection or total mastectomy (required: 2 doses of weekly MK-2206 prior to surgery; the first dose will be at day -9 [+/- 1 day] and second dose at day -2 [+/- 1 day] in relation to surgery [day 0])
- •Patients may have a history of contralateral breast cancer, provided there is no evidence of recurrence of the initial primary breast cancer
- •Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (Karnofsky >= 80%)
- •Leukocytes >= 3,000/ul within 28 days of registration
- •Platelets >= 100,000 /uL within 28 days of registration
- •Hemoglobin (Hgb) >= 9 g/dL within 28 days of registration
- •Creatinine =< 1.5 x upper limit of normal (ULN) within 28 days of registration
- •Prothrombin time (PT), partial thromboplastin time (PTT) =< 1.2 x ULN within 28 days of registration
- •Total bilirubin =< 1.5 x ULN within 28 days of registration
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN within 28 days of registration
- •Patients of childbearing potential must have a negative serum or urine pregnancy test beta-human chorionic gonadotropin (β-hCG) within 72 hours prior to receiving the first dose of study medication
- •Women of childbearing potential and men must use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the patient should inform the treating physician immediately
- •Patient must be able to swallow oral tablets
- •Ability to understand and the willingness to sign a written informed consent document
- •Patients must agree to biomarker assessment of pre-treatment diagnostic core biopsy tissue and the surgical resection tissue (i.e. excision or mastectomy); also, must agree to pre- and post-treatment fasting blood biomarker collection
排除标准
- •Patients may not have any known evidence of distant metastatic disease (i.e., lung, liver, bone, or brain metastases) or locally recurrent breast cancer
- •Patients with inflammatory breast cancer are not eligible
- •Patients with prior chemotherapy or radiation therapy within 6 months of study entry are not eligible (i.e. patient who have received neoadjuvant therapy are not eligible)
- •Patients may not be receiving any other investigational agents, including other inhibitors of PI3K, Akt, or mammalian target of rapamycin (mTOR)
- •Men diagnosed with breast cancer
- •Patients may not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206 used in the study
- •Patients with known diabetes which is poorly controlled diabetes (hemoglobin A1c [HBA1C] >= 8%) should be excluded; if patient is taking metformin, must have been taking this medication for > 3 months, as metformin is thought to impact PI3K/Akt signaling
- •Baseline corrected QT interval (QTc) > 470 msec will exclude patients from entry on study; patients with a baseline bundle branch block will be excluded
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK2206
- •Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
研究组 & 干预措施
Treatment (Akt inhibitor MK2206)
Experimental
Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy (therapeutic conventional surgery) on day 0. Patient samples will be processed for pharmacological study and laboratory biomarker analysis.
干预措施: Akt Inhibitor MK2206 (Drug)
Treatment (Akt inhibitor MK2206)
Experimental
Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy (therapeutic conventional surgery) on day 0. Patient samples will be processed for pharmacological study and laboratory biomarker analysis.
干预措施: Therapeutic Conventional Surgery (Procedure)
Treatment (Akt inhibitor MK2206)
Experimental
Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy (therapeutic conventional surgery) on day 0. Patient samples will be processed for pharmacological study and laboratory biomarker analysis.
干预措施: Pharmacological Study (Other)
Treatment (Akt inhibitor MK2206)
Experimental
Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy (therapeutic conventional surgery) on day 0. Patient samples will be processed for pharmacological study and laboratory biomarker analysis.
干预措施: Laboratory Biomarker Analysis (Other)
结局指标
主要结局
Change in pAKT Levels
时间窗: Baseline, 2 weeks (Day 0 - surgery)
This is designed to evaluate response to therapy - comparing changes within group (example: invasive pre-MK-2206-treated core versus post-MK-2206-treated surgical tissue).
次要结局
- Change in pS6 Levels(Baseline, 2 weeks (Day 0 - surgery))
- Change in Ki-67 Expression(Baseline, 2 weeks (Day 0 - surgery))
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction CancerAdenocarcinoma of the Gastroesophageal JunctionDiffuse Gastric AdenocarcinomaGastric Intestinal Type AdenocarcinomaGastric Mixed AdenocarcinomaRecurrent Gastric CarcinomaNCT01260701National Cancer Institute (NCI)75
已完成
2 期
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck CancerRecurrent Squamous Cell Carcinoma of the NasopharynxStage IV Squamous Cell Carcinoma of the NasopharynxNCT01349933National Cancer Institute (NCI)21
已完成
2 期
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst CarcinomaRecurrent Oral Cavity Adenoid Cystic CarcinomaRecurrent Salivary Gland CarcinomaSalivary Gland Adenoid Cystic CarcinomaStage IVA Major Salivary Gland Cancer AJCC v7Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7Stage IVB Major Salivary Gland Cancer AJCC v7Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7Stage IVC Major Salivary Gland Cancer AJCC v7Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7NCT01604772National Cancer Institute (NCI)16
已完成
1 期
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaAccelerated Phase Chronic Myelogenous LeukemiaAcute Leukemias of Ambiguous LineageAcute Myeloid Leukemia/Transient Myeloproliferative DisorderAggressive NK-cell LeukemiaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlastic Phase Chronic Myelogenous LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmChildhood Burkitt LymphomaChildhood Chronic Myelogenous LeukemiaChildhood Diffuse Large Cell LymphomaChildhood Grade III Lymphomatoid GranulomatosisChildhood Immunoblastic Large Cell LymphomaChildhood Nasal Type Extranodal NK/T-cell LymphomaChronic Neutrophilic LeukemiaChronic Phase Chronic Myelogenous LeukemiaIntraocular LymphomaMast Cell LeukemiaMyeloid/NK-cell Acute LeukemiaNoncutaneous Extranodal LymphomaPrimary Central Nervous System Hodgkin LymphomaPrimary Central Nervous System Non-Hodgkin LymphomaProgressive Hairy Cell Leukemia, Initial TreatmentRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Anaplastic Large Cell LymphomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Large Cell LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Small Lymphocytic LymphomaRecurrent/Refractory Childhood Hodgkin LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Hairy Cell LeukemiaRelapsing Chronic Myelogenous LeukemiaSecondary Acute Myeloid LeukemiaSmall Intestine LymphomaSplenic Marginal Zone LymphomaUnspecified Childhood Solid Tumor, Protocol SpecificWaldenström MacroglobulinemiaChronic Myelomonocytic LeukemiaProlymphocytic LeukemiaPost-transplant Lymphoproliferative DisorderAcute Undifferentiated LeukemiaJuvenile Myelomonocytic LeukemiaChronic Eosinophilic LeukemiaNCT01231919National Cancer Institute (NCI)45
已完成
2 期
Study of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaAdult Nasal Type Extranodal NK/T-cell LymphomaAngioimmunoblastic T-cell LymphomaB-cell Adult Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic LeukemiaCutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHepatosplenic T-cell LymphomaIntraocular LymphomaNodal Marginal Zone B-cell LymphomaNoncutaneous Extranodal LymphomaPeripheral T-cell LymphomaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Small Lymphocytic LymphomaRefractory Hairy Cell LeukemiaSmall Intestine LymphomaSplenic Marginal Zone LymphomaT-cell Adult Acute Lymphoblastic LeukemiaT-cell Large Granular Lymphocyte LeukemiaTesticular LymphomaWaldenström MacroglobulinemiaAnaplastic Large Cell LymphomaNCT01258998National Cancer Institute (NCI)60